Hepatitis B virus reactivation after kidney transplantation and new onset lymphoma

Journal of Clinical Gastroenterology

Volumn 36, Issue 3, 2003, Pages 276-280

  Larghi, Alberto ^a   Leffler, Daniel ^a   Frucht, Harold ^a   Rubin, Moshe ^a   Semrad, Carol E ^a   Lefkowitch, Jay H ^a   Worman, Howard J ^a  

^a Department of Medicine ^*  (United States)

Author keywords

Hepatitis B virus; Immunosuppression; Transplantation; Viral reactivation

Indexed keywords

AMINOTRANSFERASE; ANTIBIOTIC AGENT; AZATHIOPRINE; CYCLOSPORIN A; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUCONAZOLE; FUROSEMIDE; GANCICLOVIR; HEPATITIS B CORE ANTIBODY; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; HYDROCHLOROTHIAZIDE; LAMIVUDINE; STEROID; SULFONYLUREA DERIVATIVE;

AGED; ARTICLE; AUTOPSY; B CELL LYMPHOMA; CANDIDA GLABRATA; CANDIDIASIS; CASE REPORT; CAUSE OF DEATH; CLINICAL FEATURE; CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; EARLY DIAGNOSIS; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERTENSION; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; KIDNEY TRANSPLANTATION; LUNG EDEMA; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK FACTOR; VIRUS REACTIVATION; VIRUS REPLICATION;

AGED; COMORBIDITY; FATAL OUTCOME; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; IMMUNOCOMPROMISED HOST; KIDNEY TRANSPLANTATION; LIVER; LYMPHOMA, LARGE-CELL, DIFFUSE; MALE; VIRUS ACTIVATION;

EID: 0037372135     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004836-200303000-00018     Document Type: Article

References (43)

1. Colquhoun SD, Belle SH, Samuel D, et al. Transplantation in the hepatitis B patient and current therapies to prevent recurrence. Semin Liver Dis 2000;20(Suppl 1):7-12.
2. Lau GK, Lee CK, Liang R. Hepatitis B virus infection and bone marrow transplantation. Crit Rev Oncol Hematol 1999;31:71-6.
3. Pol S, Samuel D, Cadranel J, et al. Hepatitis and solid organ transplantation. Transplant Proc 2000;32:454-7.
4. Martin BA, Rowe JM, Kouides PA, et al. Hepatitis B reactivation following allogeneic bone marrow transplantation: Case report and review of the literature. Bone Marrow Transplant 1995;15:145-8.
5. Lok AS, Liang RH, Chiu EK, et al. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991;100:182-8.
6. Blanpain C, Knoop C, Delforge ML, et al. Reactivation of hepatitis B after transplantation in patients with pre-existing anti-hepatitis B surface antigen antibodies: Report on three cases and review of the literature. Transplantation 1998;66:883-6.
7. Dhedin N, Douvin C, Kuentz M, et al. Reverse seroconversion of hepatitis B after allogeneic bone marrow transplantation: a retrospective study of 37 patients with pretransplant anti-HBs and anti-HBc. Transplantation 1998;66:616-9.
8. Dickson RC, Everhart JE, Lake JR, et al. Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. Gastroenterology 1997;113:1668-74.
9. Moriyama K, Nakajima E, Hohjoh H, et al. Immunoselected hepatitis B virus mutant [letter]. Lancet 1991;337:125.
10. Kato J, Hasegawa K, Torii N, et al. A molecular analysis of viral persistence in surface antigen-negative chronic hepatitis B. Hepatology 1996;23:389-95.
11. Brechot C, Degos F, Lugassy C, et al. Hepatitis B virus DNA in patients with chronic liver disease and negative tests for hepatitis B surface antigen. N Engl J Med 1985;312:270-6.
12. Rehermann B, Ferrari C, Pasquinelli C, et al. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 1996;2:1104-8.
13. Blackberg J, Kidd-Ljunggren K. Occult hepatitis B virus after acute self-limited infection persisting for 30 years without sequence variation. J Hepatol 2000;33:992-7.
14. Zito DR, Gurdak RG, Tucker FL, et al. Hepatitis B virus serology. Loss of antibody to surface antigen. Am J Clin Pathol 1987;88:229-31.
15. Lazizi Y, Grangeot-Keros L, Delfraissy JF, et al. Reappearance of hepatitis B virus in immune patients infected with the human immunodeficiency virus type 1. J Infect Dis 1988;158:666-667.
16. Vento S, Di Perri G, Garofano T, et al. Reactivation of hepatitis B in AIDS. Lancet 1989;2:108-9.
17. Bouslama K, Knani L, Cabane J, et al. Reactivation of B hepatitis in an anti-HBs positive patient in HIV co-infection. Ann Med Intern 1991;142:63-4.
18. Webster A, Brenner MK, Prentice HG, et al. Fatal hepatitis B reactivation after autologous bone marrow transplantation. Bone Marrow Transplant 1989;4:207-8.
19. Chen PM, Fan S, Liu CJ, et al. Changing of hepatitis B virus markers in patients with bone marrow transplantation. Transplantation 1990;49:708-13.
20. Chen PM, Fan S, Liu JH, et al. Reactivation of hepatitis B virus in two chronic GVHD patients after transplant. Int J Hematol 1993;58:183-8.
21. Locasciulli A, Testa M, Valsecchi MG, et al. Morbidity and mortality due to liver disease in children undergoing allogeneic bone marrow transplantation: A 10-year prospective study. Blood 1997;90:3799-805.
22. Romand F, Michallet M, Pichoud C, et al. Hepatitis B virus reactivation after allogeneic bone marrow transplantation in a patient previously cured of hepatitis B. Gastroenterol Clin Biol 1999:23:770-4.
23. Nordbø SA, Skaug K, Holter E, et al. Reactivation of hepatitis B virus infection in an anti-HBc and anti-HBs positive patient after allogeneic bone marrow transplantation. Eur J Haematol 2000;65:86-7.
24. Iwai K, Tashima M, Itoh M, et al. Fulminant hepatitis B following bone marrow transplantation in an HBsAg-negative, HBsAb-positive recipient: Reactivation of dormant virus during the immunosuppressive period. Bone Marrow Transplant 2000;25:105-8.
25. Hashino S, Nozawa A, Izumiyama K, et al. Lamivudine treatment for reverse seroconversion of hepatitis B 4 years after allogeneic bone marrow transplantation. Bone Marrow Transplant 2002;29:361-3.
26. Locasciulli A, Santamaria M, Masera G, et al. Hepatitis B virus markers in children with acute leukemia: The effect of chemotherapy. J Med Virol 1985;15:29-33.
27. Grumayer ER, Panzer S, Ferenci P, et al. Recurrence of hepatitis B in children with serologic evidence of past hepatitis B virus infection undergoing antileukemic chemotherapy. J Hepatol 1989;8:232-5.
28. Marcellin P, Giostra E, Martinot-Peignoux M, et al. Redevelopment of hepatitis B surface antigen after renal transplantation. Gastroenterology 1991;100:1432-4.
29. Grotz W, Rasenack J, Benzing T, et al. Occurrence and management of hepatitis B virus reactivation following kidney transplantation. Clin Nephrol 1998;49:385-8.
30. Kidd-Ljunggren K, Simonsen O. Reappearance of hepatitis B 10 years after kidney transplantation. N Engl J Med 1999;341:127-8.
31. Roche B, Samuel D, Gigou M, et al. De novo and apparent de novo hepatitis B virus infection after liver transplantation. J Hepatol 1997;26:517-26.
32. Senecal D, Pichon E, Dubois F, et al. Acute hepatitis B after autologous stem cell transplantation in a man previously infected by hepatitis B virus. Bone Marrow Transplant 1999;24:1243-4.
33. Endo T, Sawada K, Fujimoto K, et al. Reactivation of hepatitis B virus after autologous peripheral blood stem cell transplantation in patients with positive hepatitis B surface antibodies. Rinsho Ketsueki 2000;41:322-8.
34. Perrillo RP. Acute flare in chronic hepatitis B: The natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 2001;120:1009-22.
35. Saba N, Abraham R, Keating A. Overview of autologous stem cell transplantation. Crit Rev Oncol Hematol 2000;36:27-48.
36. Dusheiko G. Lamivudine treatment of chronic hepatitis B. Rev Med Virol 1998;8:153-9.
37. Rossi G, Pelizzari A, Motta M, et al. Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HBsAg carriers with lymphoid malignancies treated with chemotherapy. Br J Haematol 2001;115:58-62.
38. Kawai Y, Ikegaya S, Hata M, et al. Successful lamivudine therapy for postchemotherapeutic fulminant hepatitis B in a hepatitis B virus carrier with nonHodgkin's lymphoma: case report and review of the literature. Ann Hematol 2001;80:482-4.
39. Han DJ, Kim TH, Park SK, et al. Results on preemptive or prophylactic treatment of lamivudine in HBsAg (+) renal allograft recipients: comparison with salvage treatment after hepatic dysfunction with HBV recurrence. Transplantation 2001;71:387-94.
40. Tsai MK, Lai MY, Hu RH, et al. Managing hepatitis B reactivation in renal transplant recipients: A 12-year review with emphasis on early detection and early use of lamivudine. Transplant Proc 2000;32:1935-6.
41. Sunami K, Fujiwara T, Yoshida C, et al. Prevention of hepatitis B flare-up using lamivudine in a patient with non-Hodgkin's lymphoma after allogeneic bone marrow transplantation. Rinsho Ketsueki 2000;41:733-8.
42. Picardi M, Selleri C, De Rosa G, et al. Lamivudine treatment for chronic replicative hepatitis B virus infection after allogeneic bone marrow transplantation. Bone Marrow Transplant 1998;21:1267-9.
43. Henkes M, Martin S, Einsele H, et al. Successful antiviral treatment for fulminant reactivated hepatitis B after autologous stem cell transplantation and prophylaxis during subsequent allogeneic stem cell transplantation. Ann Hematol 2002;81:343-6.